Labels

TMB Explained: Tumor Mutational Burden, TMB-High, Immunotherapy and Precision Cancer Treatment

Tumor Mutational Burden (TMB) is an important genomic biomarker used to estimate how many mutations are present in a cancer. Because tumors with many mutations may produce more abnormal proteins, or neoantigens, that can potentially be recognized by the immune system, TMB has become an important biomarker in the development and use of cancer immunotherapy.

But TMB is frequently oversimplified. A high TMB does not guarantee that immunotherapy will work, while a low TMB does not automatically mean that immunotherapy cannot work.

This SmartCancer guide explains what TMB is, how it is measured, what TMB-H means, how TMB differs from MSI-H and dMMR, how TMB relates to PD-L1, what TMB means for immunotherapy, the limitations of TMB testing, and how TMB fits into the SmartCancer Oncology Knowledge Graph.

Quick definition: Tumor mutational burden is the number of mutations found in the DNA of cancer cells. It is commonly reported as mutations per megabase (mut/Mb). Some tumors with high TMB appear more likely to respond to immune checkpoint inhibitors, but TMB is an imperfect predictive biomarker. National Cancer Institute.

TMB at a Glance

  • Full name: Tumor Mutational Burden
  • Abbreviation: TMB
  • What it measures: The number of somatic mutations detected in a tumor
  • Common unit: Mutations per megabase (mut/Mb)
  • Typical testing method: Next-generation sequencing (NGS)
  • Common clinical concept: TMB-high (TMB-H)
  • Potential biological rationale: More mutations may generate more neoantigens that can be recognized by the immune system
  • Major clinical connection: Immune checkpoint inhibitors
  • Important limitation: TMB does not directly measure immune response
CANCER DNA
↓
GENOMIC SEQUENCING
↓
MUTATIONS IDENTIFIED
↓
TMB CALCULATED
↓
TMB-H / TMB-LOW
↓
INTEGRATE WITH OTHER BIOMARKERS
↓
IMMUNOTHERAPY DECISION

Table of Contents

What Is Tumor Mutational Burden?

Tumor Mutational Burden (TMB) is a measurement of the number of mutations present in a cancer's DNA.

In clinical practice, TMB is generally expressed as the number of mutations detected per megabase of DNA that has been analyzed.

For example:

TMB = 12 mutations/Mb

This means that the tumor sequencing assay detected approximately 12 qualifying mutations for every megabase of genomic territory included in the TMB calculation.

TMB is therefore a quantitative genomic biomarker.

It does not tell you which specific mutation is driving the cancer. Instead, it describes the overall density of mutations detected by the particular test.

The NCI defines TMB as the total number of mutations found in the DNA of cancer cells.

TMB Explained Simply

Imagine two tumors:

Tumor A

Relatively few mutations.

Lower TMB

Tumor B

Many mutations.

Higher TMB

The theory behind TMB is that a heavily mutated tumor may produce more abnormal proteins that the immune system can potentially recognize as foreign.

This can create more opportunities for immune cells to identify cancer cells.

However, the immune system still has to:

  • Recognize the abnormal proteins
  • Process and present tumor antigens
  • Activate appropriate T cells
  • Get those T cells into the tumor
  • Overcome immune-suppressive mechanisms
  • Remain functional within the tumor microenvironment
  • Successfully kill tumor cells

Therefore:

High TMB increases biological potential for immune recognition; it does not guarantee an effective immune response.

What Does Mutations per Megabase Mean?

TMB is commonly expressed as:

mutations per megabase (mut/Mb)

A megabase is one million DNA base pairs.

Because sequencing tests do not necessarily examine every nucleotide in the genome, TMB is generally estimated from the genomic regions covered by the sequencing assay.

A simplified calculation is:

TMB
=
NUMBER OF QUALIFYING SOMATIC MUTATIONS
÷
MEGABASES ANALYZED

Real-world laboratory calculations are more complicated because the assay must determine which variants qualify for inclusion and account for factors such as sequencing quality, tumor purity, germline variation and bioinformatic filtering.

Why Might High TMB Predict Immunotherapy Response?

The central biological hypothesis is:

MORE TUMOR MUTATIONS
↓
POTENTIALLY MORE ABNORMAL PROTEINS
↓
MORE POTENTIAL NEOANTIGENS
↓
GREATER CHANCE OF IMMUNE RECOGNITION
↓
POTENTIALLY GREATER RESPONSE TO CHECKPOINT BLOCKADE

Research reviews have described TMB as an emerging biomarker for response to PD-1/PD-L1 immune checkpoint inhibitors, based on the possibility that a higher somatic mutation burden produces more neoantigens that can be recognized by T cells. PubMed review.

But this is a probabilistic relationship rather than a biological law.

TMB and Neoantigens

Neoantigens are abnormal peptides generated by tumor-specific genetic alterations that can potentially be recognized by the immune system.

They are one reason researchers became interested in TMB as an immunotherapy biomarker.

A tumor with many mutations may have a larger pool of potential neoantigens.

But:

  • Not every mutation produces a neoantigen.
  • Not every neoantigen is presented to T cells.
  • Not every presented neoantigen triggers an effective immune response.
  • T-cell function can be suppressed by the tumor microenvironment.
  • Tumors can lose or alter antigen presentation.

Therefore, TMB is an indirect proxy for immunogenic potential, not a direct measurement of neoantigen quality or immune activity.

How Is TMB Tested?

TMB is generally determined through genomic sequencing.

Testing may be performed using a large targeted sequencing panel or another validated genomic assay.

TUMOR SAMPLE
↓
DNA EXTRACTION
↓
NEXT-GENERATION SEQUENCING
↓
VARIANT IDENTIFICATION
↓
GERMLINE / ARTIFACT FILTERING
↓
QUALIFYING MUTATIONS COUNTED
↓
TMB CALCULATION
↓
REPORT IN MUT/Mb

The NCI explains that biomarker testing can use sequencing approaches to examine genetic changes in a tumor and that TMB can help determine whether immune checkpoint inhibitor therapy may be appropriate in some settings. NCI: Biomarker Testing for Cancer Treatment.

TMB and Next-Generation Sequencing

Next-generation sequencing (NGS) allows laboratories to analyze many genes simultaneously.

This makes NGS particularly useful for precision oncology because one test may provide information about:

  • Actionable driver mutations
  • Gene fusions
  • Copy-number alterations
  • DNA repair alterations
  • MSI-related information
  • TMB
  • Potential clinical-trial biomarkers

However, not every NGS panel produces identical TMB results.

This is one of the most important concepts patients and clinicians should understand.

TMB is assay-dependent. Two different sequencing platforms can potentially produce different TMB values from the same tumor sample.

Tissue TMB vs Blood TMB

TMB can potentially be estimated from tumor tissue or, in some contexts, from circulating tumor DNA obtained through a blood sample.

Tissue TMB

Tissue-based TMB is calculated from DNA extracted from a tumor specimen.

Advantages may include:

  • Direct sampling of tumor DNA
  • Established clinical experience
  • Integration with broad tissue NGS panels

Limitations include:

  • Insufficient tissue
  • Low tumor purity
  • Degraded specimens
  • Tumor heterogeneity
  • Difficulty obtaining a representative biopsy

Blood TMB

Blood-based testing may estimate TMB from circulating tumor DNA.

This approach is attractive because blood collection is less invasive than tissue biopsy.

However, blood-based TMB has additional technical considerations, including tumor fraction and the size and composition of the sequencing panel.

ASCO's biomarker guidance has emphasized that TMB assessment can be influenced by sample type, panel size, sequencing depth, variant-selection criteria and other technical variables, and that blood-based TMB remains an evolving area of evidence. ASCO guideline update.

Do not automatically treat a blood TMB value and tissue TMB value as interchangeable.

What Is TMB-High?

TMB-high (TMB-H) describes tumors with a high tumor mutational burden according to a defined assay and clinical threshold.

There is no universal biological number that separates every "high" tumor from every "low" tumor.

One particularly important regulatory threshold is:

≥10 mutations per megabase (mut/Mb)

The U.S. Food and Drug Administration authorized pembrolizumab for certain adults and pediatric patients with unresectable or metastatic TMB-H solid tumors defined as ≥10 mut/Mb by an FDA-authorized test, after prior treatment and when there are no satisfactory alternative treatment options. The indication remains an accelerated approval based on response rate and durability of response. FDA ongoing accelerated approvals; 2026 Keytruda QLEX labeling.

Why Is 10 Mut/Mb Important?

The 10 mut/Mb threshold has become clinically important because it is associated with the FDA-approved TMB-H indication for pembrolizumab.

But it is essential to understand what this number does—and does not—mean.

It does not mean:

  • 10 mut/Mb is a universal biological definition of a high-TMB cancer.
  • Every tumor above 10 mut/Mb will respond to immunotherapy.
  • Every tumor below 10 mut/Mb will fail immunotherapy.
  • TMB values from different assays can automatically be compared.

Instead, 10 mut/Mb is a treatment-associated threshold in a specific regulatory context.

The FDA specifically identifies FoundationOne CDx as an authorized companion diagnostic for the TMB-H pembrolizumab indication at ≥10 mut/Mb. FDA companion diagnostic database.

FDA-Recognized TMB-H Treatment

The FDA's TMB-H indication is particularly important because it is a tumor-agnostic biomarker-based indication.

Rather than being restricted to one anatomical cancer type, the indication applies to certain unresectable or metastatic solid tumors meeting the TMB-H criteria.

The current FDA labeling specifies:

  • Unresectable or metastatic solid tumor
  • TMB-H defined as ≥10 mut/Mb
  • Determined using an FDA-authorized test
  • Disease progressed following prior treatment
  • No satisfactory alternative treatment options

The FDA's accelerated-approval database continues to list the TMB-H pembrolizumab indication as an ongoing accelerated approval requiring confirmatory evidence. FDA accelerated-approval database.

Important: A TMB-H result should not be interpreted as an automatic prescription for pembrolizumab. Eligibility depends on the full regulatory indication, current labeling, clinical context, prior treatment and availability of alternative therapies.

TMB vs PD-L1

TMB and PD-L1 measure different aspects of tumor biology.

Feature PD-L1 TMB
What it measures PD-L1 protein expression Number/density of qualifying tumor mutations
Typical test IHC NGS
Typical unit TPS, CPS or other score Mutations/Mb
Biological concept Immune checkpoint signaling Genomic mutation burden
Can vary spatially? Yes Yes
Predicts immunotherapy perfectly? No No

This distinction is critical.

A tumor could have:

  • High PD-L1 and low TMB
  • Low PD-L1 and high TMB
  • High PD-L1 and high TMB
  • Low PD-L1 and low TMB

These combinations can represent different biological states.

Research has explored combining PD-L1, TMB and immune-cell characteristics because no single biomarker captures the entire complexity of the immune response. NCI discussion of immunotherapy biomarkers.

TMB vs MSI-H

MSI-H means microsatellite instability-high.

It is a different biomarker from TMB, although the two are biologically related.

Defects in DNA mismatch repair can cause microsatellite instability and accumulation of mutations.

DNA MISMATCH REPAIR DEFECT
↓
ACCUMULATION OF DNA ERRORS
↓
MSI-H
↓
OFTEN HIGH MUTATIONAL BURDEN
↓
MORE POTENTIAL NEOANTIGENS
↓
POTENTIAL IMMUNE RECOGNITION

However, MSI-H and TMB-H are not interchangeable diagnoses.

A tumor can be:

  • MSI-H and TMB-H
  • MSI-stable and TMB-H
  • MSI-H with variable TMB depending on tumor biology and assay
  • Neither MSI-H nor TMB-H

MSI-H/dMMR is itself an important immunotherapy biomarker and has tumor-specific and tumor-agnostic treatment implications that should be considered independently of TMB.

TMB vs dMMR

dMMR means deficient mismatch repair.

Mismatch repair proteins normally help correct errors that occur when DNA is copied.

When this repair system is defective, tumors can accumulate mutations.

Therefore:

dMMR
is a DNA repair phenotype

MSI-H
is a genomic instability phenotype

TMB-H
is a measure of mutation density

These biomarkers can overlap substantially, but they answer different biological questions.

TMB in Lung Cancer

TMB has been extensively studied in lung cancer because smoking-associated tumors can accumulate large numbers of mutations.

However, modern lung cancer treatment selection should not be reduced to TMB.

Advanced non-small cell lung cancer requires attention to a broader molecular and immune biomarker landscape.

This may include:

  • EGFR
  • ALK
  • ROS1
  • KRAS
  • BRAF
  • MET
  • RET
  • NTRK
  • HER2
  • PD-L1
  • Other clinically relevant genomic alterations

Current CAP/AMP/IASLC/PPS/LUNGevity guidance emphasizes validated biomarker testing and integration of PD-L1 with appropriate genomic testing when selecting immune checkpoint inhibitor therapies in advanced NSCLC. CAP guideline.

SmartCancer principle: In lung cancer, a high TMB should not cause clinicians to overlook an actionable driver alteration for which targeted therapy may be more appropriate.

TMB in Breast Cancer

TMB is generally lower in breast cancer than in some highly mutated tumor types, although a subset of breast cancers can have high TMB.

NCI notes that TMB-H breast cancers represent a minority of cases and that TMB varies substantially among breast-cancer subtypes. NCI Breast Cancer Treatment PDQ.

TMB may therefore provide useful information in selected advanced breast cancers, but it should be interpreted alongside:

  • ER status
  • PR status
  • HER2 status
  • PD-L1 where clinically relevant
  • BRCA1/2 and homologous-recombination biomarkers when relevant
  • MSI/dMMR
  • Prior treatment
  • Disease burden and clinical condition

TMB Across Other Cancers

TMB varies dramatically between tumor types.

Some cancers are characterized by relatively high mutation rates, while others typically have lower mutation burdens.

Examples of factors associated with high mutation burden can include:

  • Defective DNA mismatch repair
  • Microsatellite instability
  • Ultraviolet-associated mutagenesis
  • Tobacco-associated mutagenesis
  • Some DNA polymerase abnormalities
  • Other defects in DNA repair or replication

But the relationship between mutation count and immune response remains complex.

Limitations of TMB

TMB is useful, but it is far from perfect.

1. Different assays can produce different results

Sequencing panels differ in:

  • Panel size
  • Genes included
  • Genomic territory analyzed
  • Sequencing depth
  • Variant-calling algorithms
  • Germline filtering
  • Mutation categories included

The 2024 AMP/ASCO/CAP/SITC consensus recommendations emphasize the importance of analytical validation and detailed reporting because these methodological factors affect TMB comparability. AMP TMB testing recommendations.

2. TMB does not measure mutation quality

Two tumors could have the same TMB but very different mutation profiles.

The biological consequences of those mutations may be very different.

3. Not every mutation creates an immunogenic neoantigen

A high mutation count does not necessarily translate into effective immune recognition.

4. Tumor microenvironment matters

An immune-excluded or highly immunosuppressive tumor may remain resistant despite high TMB.

5. Antigen presentation matters

Even if neoantigens exist, tumors may evade immune recognition through alterations in antigen-processing and presentation pathways.

6. Tumor heterogeneity matters

A biopsy samples only part of a tumor or metastatic system.

7. Cutoffs are context-dependent

A numerical threshold developed for one assay or clinical indication should not automatically be transferred to another.

8. TMB is not a direct measure of immune activity

It is a genomic measurement that may correlate with immunogenicity under certain circumstances.

Core SmartCancer message: TMB is a useful clue about tumor biology—not a crystal ball.

Tumor Heterogeneity and TMB

Cancer is not genetically uniform.

Different regions of the same tumor can contain different mutations, and metastases can evolve differently from the primary tumor.

PRIMARY TUMOR
↓
GENETIC EVOLUTION
↓
SUBCLONES
↓
METASTASES
↓
DIFFERENT MUTATIONAL LANDSCAPES

This creates a practical problem:

Which tumor should be tested?

A biopsy taken from one site may not perfectly represent the complete mutational landscape of the patient's cancer.

This is one reason molecular results should be interpreted alongside clinical imaging, pathology, treatment history and other biomarkers.

Can TMB Be Misleading?

Yes.

A very high TMB may be biologically meaningful, but the number itself does not explain why the tumor is highly mutated.

Possible explanations include:

  • Mismatch-repair deficiency
  • MSI-H biology
  • POLE/POLD1-related mutagenesis
  • Ultraviolet-associated mutagenesis
  • Tobacco-associated mutagenesis
  • Other DNA repair defects
  • Technical artifacts
  • Germline variants incorrectly included in analysis

Understanding the mechanism behind a high TMB can sometimes provide more biological insight than the number alone.

How to Read a TMB Report

If a genomic report says:

TMB: 14 mut/Mb

do not stop there.

Look for:

  1. Testing platform
  2. Assay name
  3. Specimen type
  4. Tumor percentage / purity
  5. Panel size
  6. TMB value
  7. Laboratory reference category
  8. MSI status
  9. MMR status
  10. PD-L1 status
  11. Actionable driver alterations
  12. Potential clinical trials

Important: A TMB number without the assay and clinical context is incomplete information.

How TMB Fits Into Clinical Decision-Making

The modern precision-oncology model is increasingly multidimensional.

A simplified decision framework is:

CANCER TYPE
↓
STAGE
↓
HISTOLOGY
↓
MOLECULAR PROFILE
↓
PD-L1
+
TMB
+
MSI / dMMR
+
ACTIONABLE MUTATIONS
↓
PREVIOUS TREATMENTS
↓
CLINICAL STATUS
↓
TREATMENT OPTIONS

This is the essence of precision oncology.

The objective is not to find one "magic biomarker."

The objective is to integrate multiple pieces of evidence into a clinically meaningful treatment strategy.

TMB and Immunotherapy Resistance

High TMB may increase the likelihood of immunotherapy benefit, but tumors can still develop resistance.

Potential mechanisms include:

  • Loss of tumor antigens
  • Altered antigen presentation
  • Defects in interferon signaling
  • Changes in immune-cell infiltration
  • Immunosuppressive tumor microenvironment
  • Alternative immune checkpoints
  • Clonal selection
  • Tumor evolution

This is why a tumor that initially responds to checkpoint inhibition may later progress.

HIGH TMB
↓
IMMUNOTHERAPY
↓
INITIAL RESPONSE
↓
SELECTIVE PRESSURE
↓
TUMOR EVOLUTION
↓
RESISTANT CLONES
↓
DISEASE PROGRESSION

NCI research has emphasized that mutation number alone is not sufficient to explain immunotherapy response; the type and diversity of mutations and the surrounding immune environment may also matter. NCI: Immunotherapy biomarkers.

TMB and Clinical Trials

TMB is an important biomarker in cancer clinical research.

Trials may investigate:

  • TMB-guided checkpoint inhibitor therapy
  • Combination immunotherapy
  • PD-1/PD-L1 inhibitors plus chemotherapy
  • Immunotherapy plus targeted therapy
  • Immunotherapy plus radiation
  • New immune checkpoint targets
  • Neoantigen vaccines
  • Personalized cancer vaccines
  • AI-based immunotherapy prediction
  • Multi-biomarker response models

For patients with advanced cancer, a comprehensive molecular profile may therefore identify not only approved treatment options but also potential clinical-trial opportunities. The NCI explains that biomarker testing can help match patients to treatments and clinical trials. NCI biomarker testing guide.

TMB in the SmartCancer Oncology Knowledge Graph

TMB should be treated as a major node in the SmartCancer Oncology Knowledge Graph.

TUMOR
↓
GENOMIC SEQUENCING
↓
TMB
↓
TMB-H / TMB-LOW
↓
NEOANTIGEN POTENTIAL
↓
IMMUNE RECOGNITION
↓
PD-1 / PD-L1 CHECKPOINT
↓
IMMUNOTHERAPY
↓
RESPONSE / RESISTANCE
↓
NEXT-LINE STRATEGY
↓
CLINICAL TRIAL

How TMB Connects to Other Biomarkers

  • TMB ↔ PD-L1: Two different dimensions of immunotherapy biology
  • TMB ↔ MSI-H: Frequently related through DNA repair biology, but not identical
  • TMB ↔ dMMR: Mismatch-repair deficiency can produce high mutation burden
  • TMB ↔ POLE/POLD1: Polymerase alterations can produce ultramutated tumors
  • TMB ↔ DNA repair: Defective repair mechanisms can increase mutation accumulation
  • TMB ↔ Immunotherapy: High TMB may increase the probability of checkpoint-inhibitor benefit in selected settings
  • TMB ↔ Resistance: Mutation burden alone does not prevent immune escape
  • TMB ↔ Clinical trials: TMB may be used for eligibility, stratification or exploratory biomarker analysis

Recommended SmartCancer Internal Links

Replace placeholder URLs with the final SmartCancer URLs when the corresponding cluster pages are published.

The Future of TMB

The next generation of immunotherapy biomarkers is unlikely to rely on TMB alone.

Researchers are increasingly exploring combinations of genomic, transcriptomic, pathological and immune information.

Neoantigen Prediction

Identifying which mutations actually generate immunogenic targets.

AI Biomarker Models

Combining large numbers of genomic, clinical and pathological variables.

Spatial Biology

Studying where tumor and immune cells are located relative to one another.

Digital Pathology

Analyzing tissue architecture and immune-cell patterns computationally.

ctDNA Monitoring

Tracking molecular changes during treatment and disease progression.

Multi-Biomarker Scores

Combining TMB with PD-L1, MSI, immune signatures and other variables.

The ultimate goal is to move beyond:

"Is the TMB high?"

toward:

"What does this tumor's complete biological profile tell us about its likelihood of responding to this particular treatment?"

TMB: Key Takeaways

  • TMB measures the number of qualifying mutations in a tumor.
  • TMB is commonly reported as mutations per megabase.
  • High TMB may increase the probability of immune recognition.
  • High TMB can be associated with response to immune checkpoint inhibitors in selected settings.
  • TMB is not the same as PD-L1.
  • TMB is not the same as MSI-H.
  • TMB is not the same as dMMR.
  • TMB-H is a clinical classification whose threshold depends on the relevant assay and indication.
  • ≥10 mut/Mb is an important FDA treatment-associated threshold for pembrolizumab's TMB-H solid-tumor indication.
  • The FDA TMB-H pembrolizumab indication remains under accelerated approval.
  • Different sequencing assays can produce different TMB values.
  • Tissue TMB and blood TMB should not automatically be treated as interchangeable.
  • High TMB does not guarantee immunotherapy response.
  • Low TMB does not automatically rule out immunotherapy.
  • TMB should be integrated with PD-L1, MSI/dMMR, actionable mutations and clinical context.
  • The future of precision immunotherapy is likely to involve multi-biomarker and AI-assisted models rather than a single number.

Frequently Asked Questions About TMB

What does TMB stand for?

TMB stands for Tumor Mutational Burden.

What does TMB measure?

TMB estimates the number of qualifying mutations detected in a tumor's DNA, commonly reported as mutations per megabase.

What is TMB-H?

TMB-H means Tumor Mutational Burden-High. It refers to a tumor whose TMB meets the relevant high-TMB threshold for a particular assay and clinical context.

What is a high TMB score?

There is no universal biological definition of high TMB for every cancer and assay. An important FDA treatment-associated threshold is ≥10 mut/Mb for the TMB-H pembrolizumab indication using an FDA-authorized test.

Is TMB of 10 high?

It can qualify as TMB-H in the specific FDA-approved pembrolizumab indication when determined using the appropriate FDA-authorized test. It should not be interpreted as a universal definition of high TMB for every cancer or assay.

Is TMB of 20 good for immunotherapy?

A higher TMB can increase the likelihood of benefit from checkpoint inhibition in selected settings, but TMB alone cannot guarantee response. PD-L1, MSI/dMMR, tumor type, immune environment, treatment history and other factors also matter.

Is TMB the same as PD-L1?

No. PD-L1 measures expression of an immune checkpoint ligand, usually by immunohistochemistry, while TMB measures the density of qualifying mutations in tumor DNA.

Is TMB the same as MSI-H?

No. MSI-H measures microsatellite instability, while TMB measures mutation burden. They are biologically related in many tumors but are not interchangeable.

Does high TMB mean a better prognosis?

Not necessarily. TMB is primarily a biomarker of tumor biology and potential treatment response in selected contexts. It should not automatically be interpreted as a favorable or unfavorable prognostic marker across all cancers.

Does high TMB mean immunotherapy will work?

No. High TMB may increase the probability of response to immune checkpoint inhibition in selected settings, but it is an imperfect predictive biomarker.

Can low TMB tumors respond to immunotherapy?

Yes. TMB is not a perfect gatekeeper for immunotherapy response, and treatment decisions depend on the specific cancer, treatment indication and other biomarkers.

How is TMB measured?

TMB is usually estimated through genomic sequencing, often using a targeted next-generation sequencing panel.

Can TMB be measured from blood?

Some assays can estimate TMB from circulating tumor DNA. However, blood-based TMB has additional technical limitations and should not automatically be considered interchangeable with tissue-based TMB.

Why can two TMB tests give different results?

Different assays can use different gene panels, genomic territory, sequencing depth, variant filters, germline filtering and bioinformatic algorithms. These differences can affect the calculated TMB.

What cancers have high TMB?

TMB varies widely between cancers. Tumors associated with certain DNA-repair defects, ultraviolet exposure, tobacco exposure and other mutational processes can have particularly high mutation burdens.

Can TMB change over time?

The genomic composition of cancer can evolve during disease progression and treatment. Different tumor sites can also have different mutational profiles.

Should TMB be used alone to select treatment?

Generally, no. TMB should be interpreted alongside the cancer type, stage, actionable genomic alterations, PD-L1, MSI/dMMR, previous treatment and the current evidence for the proposed therapy.

Conclusion: TMB Is a Map of Tumor Mutation, Not a Crystal Ball

Tumor Mutational Burden is one of the most important genomic biomarkers in modern immuno-oncology.

It provides a quantitative estimate of how heavily mutated a tumor is and offers a biological explanation for why some tumors may be particularly susceptible to immune checkpoint inhibition.

But TMB should never be reduced to:

High TMB = immunotherapy works.

The reality is more sophisticated.

A tumor's response to immunotherapy depends on an interconnected system involving:

MUTATIONAL BURDEN
+
NEOANTIGENS
+
ANTIGEN PRESENTATION
+
PD-L1
+
T-CELL INFILTRATION
+
IMMUNE MICROENVIRONMENT
+
DNA REPAIR
+
TUMOR EVOLUTION
+
TREATMENT HISTORY
↓
IMMUNOTHERAPY RESPONSE

That is why TMB belongs in the SmartCancer Oncology Knowledge Graph as a central genomic node connecting tumor genetics, neoantigen biology, immune checkpoint signaling, immunotherapy, treatment response and resistance.

Medical disclaimer: This article is for educational purposes and is not medical advice. TMB results should be interpreted by qualified oncology and pathology professionals in the context of the specific cancer, stage, assay, treatment indication and current evidence. Biomarker thresholds, drug approvals and clinical guidelines can change. A TMB result does not guarantee treatment response or determine an individual treatment plan.

SmartCancer Oncology Knowledge Graph
Biomarkers → TMB → Neoantigens → Immune Recognition → Immunotherapy → Response → Resistance → Clinical Trials

Labels:

Comments

Post a Comment

Popular Posts